伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

目的:观察伊立替康联合雷替曲塞二线治疗晚期结直肠癌的疗效及安全性.方法 :对22例一线治疗失败的晚期结直肠癌病人予以二线治疗:伊立替康180 mg/m2,静脉滴注1 h,第1天;雷替曲塞3 mg/m2,静脉滴注15 min,第2天;21 d为1个周期.每2个周期评价疗效,并分析其安全性.结果 :22例病人均可评价近期疗效,其中完全缓解1例,部分缓解4例,疾病稳定11例,疾病进展6例,客观有效率为22.7%,疾病控制率为72.7%,病人的中位肿瘤进展时间为5.0个月,中位总生存时间11.8个月.严重不良反应为中性粒细胞减少和腹泻,发生率分别为13.6%和4.5%.结论 :伊立替康联合雷替曲塞在晚期结直肠癌的二线化疗中,有效率较高,不良反应能够耐受,值得在临床上推广.

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

Objective:To observe the efficacy and safety of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer. Methods:Twenty-two patients with advanced colorectal cancer were treated with the second-line chemotherapy after the first-line treatment failure. The patients were treated with 180 mg/m2 of irinotecan by intravenous infusion for 1 h on the first day,and 3 mg/m2 of raltitrexed by intravenous infusion for 15 minutes on the second day,21 days as a cycle. The efficacy and safety were evaluated every 2 cycles. Results:The short-term efficacy of all cases was evaluated. The complete response in 1 case, partial response in 4 cases,stable disease in 11 cases and progressive disease in 6 cases were found. The objective response and disease control rates were 22. 7% and 72. 7%,respectively. The median time of tumor progression and median overall survival time were 5. 0 and 11. 8 months, respectively. The neutrophilopenia and diarrhea were serious adverse reactions, the incidence rates of those were 13. 6% and 4. 5%,respectively. Conclusions:The irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer is high efficacy,and the adverse reactions can be tolerated,which is worthy of wider application.